Maxwell Skor
Stock Analyst at Morgan Stanley
(1.42)
# 3,499
Out of 4,981 analysts
6
Total ratings
60%
Success rate
-1.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $145.93 | -1.32% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $195.58 | +27.82% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $3.22 | +272.67% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.76 | +468.18% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.43 | +148.25% | 2 | Nov 20, 2024 |
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $145.93
Upside: -1.32%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $195.58
Upside: +27.82%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $3.22
Upside: +272.67%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.76
Upside: +468.18%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.43
Upside: +148.25%